24/7 Market News Snapshot 25 September, 2025 – Capricor Therapeutics Inc (NASDAQ:CAPR)

September 25, 2025

DENVER, Colo., 25 September, 2025 (www.247marketnews.com) – (NASDAQ:CAPR) are discussed in this article.
Capricor Therapeutics Inc. (CAPR) has witnessed a notable surge in its stock price, opening at $6.81 before trading at $7.071—reflecting a robust increase of approximately 14.23% compared to its previous session close of $6.19. This upswing indicates a strong bullish sentiment among investors, with a trading volume of 2.61 million shares pointing to heightened interest and activity surrounding the stock. Investors and analysts are advised to closely monitor technical indicators such as the Relative Strength Index (RSI) and moving averages, as continued upward movement could suggest additional buying pressure, albeit with a cautious eye on upcoming resistance levels for sustained growth.

In a parallel development, Capricor Therapeutics has announced promising progress in its regulatory framework for Deramiocel, a novel cell therapy targeting Duchenne muscular dystrophy (DMD). Following a productive meeting with the U.S. Food and Drug Administration (FDA), the company has delineated its strategy for resubmitting the Biologics License Application (BLA), with topline data from the pivotal HOPE-3 trial expected by mid-Q4 2025. The FDA has recognized that the outcomes from this clinical trial will fulfill the requirements initially expressed in a Complete Response Letter received in July 2025.

Dr. Linda Marbán, CEO of Capricor, conveyed her optimism regarding the regulatory pathway, noting the clarity achieved from discussions with the FDA. The therapy’s positive results in prior HOPE-2 trials have strengthened its profile, and the inclusion of left ventricular ejection fraction as a secondary endpoint further enhances its therapeutic credibility.

DMD impacts approximately 15,000 patients in the United States, highlighting the pressing need for effective treatment options. Deramiocel harnesses the unique properties of allogeneic cardiosphere-derived cells, aiming to improve both cardiac and skeletal muscle function. Capricor remains fortified financially to support continued advancements as it endeavors to deliver transformative therapies to those affected by DMD.

Related news for (CAPR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.